Who mentions $CUE most on Surfaced?

@investmentguru_ (InvestmentGuru) mentions $CUE most — 10 mentions in the past 12 months.

When was $CUE first mentioned on Surfaced?

The earliest tracked mention of $CUE in the Surfaced archive was on Mar 15, 2026.

How many voices track $CUE?

1 FinTwit voice has mentioned $CUE 10 times in the past 12 months.

What kind of voices mention $CUE most?

$CUE is mentioned most by Long Research voices on Surfaced.

$CUE — FinTwit mentions on Surfaced

Recent mentions

10 mentions

@investmentguru_Jun 17, 2026 · 7:30 PM

$CUE What continues to stand out about $CUE is that this isn’t a one-drug story — it’s a platform story. Cue Biopharma’s Selective Immune Modulation platform is designed to mimic the body’s natural immune signals, selectively activating disease-relevant T cells without broadly suppressing or overstimulating the immune system. The modular approach allows validated components to be rapidly combined into new therapies, creating a potentially faster and more cost-efficient path to pipeline expansion. Early clinical activity and tolerability from the CUE-100 oncology programs provide initial human validation, while the same technology is now being extended into autoimmune disease through the CUE-400 series (regulatory T cell induction) and CUE-500 series (targeted B-cell depletion). The recent addition of Ascendant-221, a Phase 2 anti-IgE antibody with a dual mechanism of action, expands the company into allergic diseases and adds a near-term data catalyst. With multiple shots on goal, a validated pharma partnership, improving financials, and an experienced biotech CEO now leading the company, $CUE remains a high-risk but increasingly interesting immunology name to watch. Paid partnership. Advertisement Disclaimer: https://t.co/qD6RaYElcw #Biotech #Immunology #Healthcare #SmallCap #Investing $CUE

Open on X

@investmentguru_Jun 17, 2026 · 3:59 PM

$CUE

Open on X

@investmentguru_Jun 17, 2026 · 2:06 PM

🧬 $CUE is becoming one of the more interesting micro-cap biotech turnaround stories on my watchlist. The company now has a ~$110M market cap, reported Q1 2026 collaboration revenue growth from $0.4M to $5.7M YoY, and cut net losses from $12.3M to $5.2M while reducing R&D expenses and extending runway through a recent $30M financing plus Boehringer Ingelheim milestone payments. The BI partnership alone carries up to $345M in potential milestones + royalties, which is massive relative to current valuation. Add in new CEO Dr. Shao-Lee Lin — who previously built ACELYRIN into a multi-billion-dollar biotech IPO — and upcoming H2 2026 CUE-221 Phase 2 allergy data becomes a major catalyst to watch. Still very high risk due to dilution overhang and clinical uncertainty, but the improving balance sheet, validated platform, and strong pharma partnership make this one worth tracking closely. $CUE #Biotech #Immunology #Healthcare #Stocks (https://t.co/uIvJa1xOLK) Disclaimer: https://t.co/qD6RaYElcw

Open on X

@investmentguru_Jun 17, 2026 · 1:29 PM

$CUE — One Small-Cap Immunology Name I’m Watching Closely This isn’t your typical biotech story. Cue Biopharma is building a precision immunology platform designed to selectively activate only disease-relevant T cells — potentially avoiding the broad toxicity seen with older immune therapies like IL-2. What caught my attention: 🔹 Boehringer Ingelheim partnership worth up to $345M + royalties 🔹 New allergic disease program (CUE-221 / Ascendant-221) with Phase 2 data expected in H2 2026 🔹 Financials improving: revenue growth, shrinking losses, stronger runway 🔹 New CEO Dr. Shao-Lee Lin previously built ACELYRIN into a $2B+ IPO and helped develop blockbuster drugs like SKYRIZI & RINVOQ 🔹 Small ~$95M market cap with very high short interest = potential volatility/squeeze setup if catalysts land positively Pipeline spans: → Oncology → Autoimmune disease → Allergy/immunology Key thing for me: the platform appears scientifically validated enough for major pharma interest, and the company now has leadership with proven biotech execution experience. Still high risk: ⚠️ Clinical-stage biotech ⚠️ Potential dilution risk ⚠️ Promotional activity around the stock means investors should separate hype from fundamentals The real focus should be: 📌 July clinical inflection event 📌 H2 2026 Phase 2 CUE-221 data 📌 Progress under the BI collaboration Interesting setup for biotech watchers who understand the risks involved. Not a financial advice. Paid partnerships, advertisement Disclaimer: https://t.co/qD6RaYElcw #Biotech #Immunology #Healthcare #Investing #SmallCap #Pharma #Biotechnology #Stocks $CUE

Open on X

@investmentguru_Jun 17, 2026 · 12:59 PM

$CUE — 5 Reasons This Immunology Story Is Getting Attention The immunology space is competitive, but Cue Biopharma is building a differentiated, precision-driven platform that continues to attract investor interest heading into key 2026 catalysts. Here’s the breakdown: 1️⃣ Precision Immunology — A Different Mechanism Instead of broadly activating the immune system, Cue’s Immuno-STAT platform is designed to selectively activate only disease-relevant T cells. Think targeted scalpel vs systemic sledgehammer — aiming for efficacy with fewer off-target toxicities. 2️⃣ Big Pharma Validation — Boehringer Ingelheim Partnership A collaboration worth up to $345M in milestones + royalties provides strong external validation. A recent $7.5M milestone payment (Apr 2026) signals continued scientific and development progress. 3️⃣ Expanding into Allergic Disease — Large Market Opportunity CUE’s licensed asset CUE-221 (Ascendant-221) targets IgE-driven conditions like food allergy and CSU. This enters a space where Xolair (~$4.7B annual sales) already proves strong commercial demand. 4️⃣ Improving Financial Trajectory Q1 2026 revenue: $5.7M vs $0.4M YoY Net loss narrowed: $5.2M vs $12.3M YoY Early signs of collaboration-driven revenue scaling while controlling burn. 5️⃣ New Leadership + Fresh Capital New CEO Shao-Lee Lin, M.D., Ph.D. brings deep biotech leadership experience (AbbVie, Gilead, Amgen, ACELYRIN founder). Recent $27.6M private placement strengthens runway into key 2H 2026 catalysts. 📊 Bottom Line Cue Biopharma is a high-risk, high-reward clinical-stage biotech (~$128M market cap) positioned around a major catalyst window in 2H 2026. The key driver ahead: CUE-221 Phase 2 data readout — a potential inflection point that will define the next chapter. High volatility. Binary outcomes. Clear catalyst path. Paid promotion, #advertisement Disclaimer: https://t.co/qD6RaYElcw I got paid for this post Not financial advice. DYOR.

Open on X

@investmentguru_May 19, 2026 · 7:30 PM

$CUE Wrapping up the day still thinking about $CUE — at ~$110M market cap you’re getting a validated immunology platform, a Boehringer Ingelheim partnership worth up to $345M in milestones + royalties, a CEO who already built one multi-billion dollar biotech, and a Phase 2 catalyst in H2 2026, all while the balance sheet is actually improving — yes it’s high risk, but the risk/reward at this valuation with this setup is hard to ignore. Watching closely into the back half of the year. Not financial advice. $CUE #Biotech #Immunology #Stocks Paid promotion @TheFlowShark Disclaimer: https://t.co/qD6RaYElcw

Open on X

@investmentguru_May 19, 2026 · 2:30 PM

$CUE The part that doesn’t get enough attention: Boehringer Ingelheim didn’t just partner with them. They keep paying milestones. That’s big pharma saying the platform still works. H2 2026 CUE-221 data will be the real test. Watching closely. Paid promotion Disclaimer: https://t.co/qD6RaYElcw Not financial advice. $CUE #Biotech #Immunology #Stocks

Open on X

@investmentguru_May 19, 2026 · 2:01 PM

$CUE — micro-cap biotech turnaround worth watching. → Market cap ~$110M → Collaboration revenue: $0.4M → $5.7M YoY → Net loss cut from $12.3M to $5.2M → $30M financing + Boehringer Ingelheim partnership ($345M potential milestones + royalties) → New CEO built ACELYRIN into a multi-billion IPO → CUE-221 Phase 2 allergy data due H2 2026 🔬 High risk — dilution overhang + clinical uncertainty — but the balance sheet is improving and the BI validation is real. Paid promotion @TheFlowShark See disclaimer in original post $CUE #Biotech #Immunology #Stocks

Open on X

@investmentguru_May 19, 2026 · 1:30 PM

$CUE One Small-Cap Immunology Name. Cue Biopharma is building a precision immunology platform designed to selectively activate only disease-relevant T cells — potentially avoiding the broad toxicity seen with older immune therapies like IL-2. 🔹 Boehringer Ingelheim partnership worth up to $345M + royalties 🔹 New allergic disease program (CUE-221 / Ascendant-221) with Phase 2 data expected in H2 2026 🔹 Financials improving: revenue growth, shrinking losses, stronger runway 🔹 New CEO Dr. Shao-Lee Lin previously built ACELYRIN into a $2B+ IPO and helped develop blockbuster drugs like SKYRIZI & RINVOQ 🔹 Small ~$95M market cap with very high short interest = potential volatility/squeeze setup if catalysts land positively Pipeline spans: → Oncology → Autoimmune disease → Allergy/immunology Key thing for me: the platform appears scientifically validated enough for major pharma interest, and the company now has leadership with proven biotech execution experience. Still high risk: Clinical-stage biotech The real focus should be: 📌 July clinical inflection event 📌 H2 2026 Phase 2 CUE-221 data 📌 Progress under the BI collaboration Interesting setup for biotech watchers who understand the risks involved. It’s a paid promotion @TheFlowShark Disclaimer: https://t.co/qD6RaYElcw #advertisement #Biotech #Immunology #Healthcare #Investing #SmallCap #Pharma #Biotechnology #Stocks

Open on X

@investmentguru_Mar 15, 2026 · 12:22 PM

6 Peptide Biotech Stocks to watch for future. $BCYC •Tumor-targeting bicyclic peptides •Oncology + peptide-drug conjugates •Could attract major pharma buyouts if trials succeed $ENTX •Oral peptide delivery—no injections needed •Osteoporosis & metabolic disease drugs •Potential to disrupt $100B injectable peptide market $LSTA •Peptides that help chemotherapy drugs penetrate tumors •Oncology-focused with Phase 2/3 catalysts $CUE •Peptide-MHC molecules activate immune cells •Precision immunotherapy for cancer & autoimmune diseases $VTGN •Neuropeptide nasal sprays •Rapid-acting treatments for social anxiety disorder •Huge potential psychiatric market if trials succeed $PEPG •Peptide-enhanced delivery of RNA therapies •Focus on rare genetic diseases, e.g., Duchenne muscular dystrophy •Solves one of biotech’s biggest challenges: getting therapies inside cells efficiently •Could become a major platform play if delivery technology proves successful The peptide revolution is already underway: •GLP-1 drugs proved the market is massive •AI-designed peptides accelerate drug discovery •Small-cap peptide biotech companies often become multi-bagger winners after clinical successes High risk, high reward — clinical-stage biotechs are volatile. But the next biotech cycle could be defined by peptides.

Open on X

Frequently asked